The prospective comparative nonrandomized clinical interventional study included 28 patients (28 eyes) with branch retinal vein occlusion. The study group consisting of 10 consecutive patients ...

The retina is the innermost layer of the eye, which is involved in receiving visual input and sending the light signal to the brain via the optic nerve. The blood supply to the retina is provided via ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...

Please provide your email address to receive an email when new articles are posted on . The study included 418,965 patients (81.1% women) with two migraine diagnoses within 1 year of each other and at ...

Patients with retinal vein occlusion who received Vabysmo experienced visual improvements as well as extended treatment intervals at 72 weeks, according to a study. At Angiogenesis, Exudation, and ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

NEW YORK, July 30 (Reuters) - Roche Holding AG's eye disease drug Lucentis proved effective in helping to improve vision in patients suffering from a condition known as central retinal vein occlusion, ...

An FDA target action date of August 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application ...

Patients with retinal artery occlusions (RAOs) had subsequent increased risks of death, stroke, and myocardial infarction (MI) over both the short and long term compared with matched controls with ...

Central retinal artery occlusion (CRAO) is a medical emergency, and systems of care need to evolve to enable prompt recognition, triage, and management in a manner similar to that of cerebral ischemic ...